Intersect ENT, Inc. (NASDAQ:XENT)‘s stock had its “hold” rating restated by equities researchers at BTIG Research in a report released on Tuesday.

Other analysts have also issued research reports about the stock. BidaskClub lowered shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 target price on shares of Intersect ENT in a research note on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 target price on shares of Intersect ENT and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, October 5th. Finally, Bank of America Corporation upped their target price on shares of Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $30.88.

Shares of Intersect ENT (XENT) opened at $28.50 on Tuesday. Intersect ENT has a one year low of $9.20 and a one year high of $33.25.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The firm had revenue of $22.31 million during the quarter, compared to analyst estimates of $21.53 million. During the same quarter in the prior year, the business posted ($0.22) EPS. The business’s revenue was up 20.8% compared to the same quarter last year. research analysts anticipate that Intersect ENT will post -0.62 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Intersect ENT, Inc. (XENT) Stock Rating Reaffirmed by BTIG Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/09/intersect-ent-inc-xent-stock-rating-reaffirmed-by-btig-research.html.

In related news, COO Richard E. Kaufman sold 22,425 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $30.22, for a total transaction of $677,683.50. Following the completion of the transaction, the chief operating officer now owns 149,821 shares in the company, valued at $4,527,590.62. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $27.78, for a total transaction of $356,500.74. Following the transaction, the chief financial officer now owns 27,833 shares of the company’s stock, valued at approximately $773,200.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 134,563 shares of company stock valued at $3,999,247. 13.70% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the business. Legal & General Group Plc boosted its position in Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares during the period. American International Group Inc. boosted its position in Intersect ENT by 7.1% during the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 1,037 shares during the period. Voya Investment Management LLC boosted its position in Intersect ENT by 9.7% during the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock worth $356,000 after purchasing an additional 1,128 shares during the period. Rhumbline Advisers boosted its position in Intersect ENT by 5.9% during the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after purchasing an additional 1,625 shares during the period. Finally, EAM Investors LLC boosted its position in Intersect ENT by 1.1% during the third quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock worth $5,117,000 after purchasing an additional 1,776 shares during the period. Hedge funds and other institutional investors own 83.08% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.